Amicus Therapeutics

FDA kills off Amicus’ 2018 accelerated approval plan
FDA kills off Amicus’ 2018 accelerated approval plan
Fierce Biotech
FDA
Amicus Therapeutics
Pompe disease
AT-GAA
Flag link:
FDA Approves Eight Novel Drugs in August
FDA Approves Eight Novel Drugs in August
BioSpace
Kyowa Hakko Kirin
Poteligeo
Alnylam
Onpattro
Amicus Therapeutics
Galafold
TherapeuticMD
Annovera
Biocodex
Diacomit
Dompe Group
Oxervate
Shire
Takhzyro
Merck
Pifeltro
Flag link:
Amicus Finally Wins FDA Nod, Will Price Fabry Drug Below Rivals
Amicus Finally Wins FDA Nod, Will Price Fabry Drug Below Rivals
Xconomy
Fabry disease
FDA
Amicus Therapeutics
Galafold
Flag link:
2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs
2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs
TheStreet.com
biotech
M&A
Bluebird Bio
Amicus Therapeutics
Flag link:
Prescribed Reading: DMD, MS and other acronyms
Prescribed Reading: DMD, MS and other acronyms
Biopharma Dive
Celgene
Nimbus
Endocyte
Amicus Therapeutics
Catabasis
Motif Biosciences
Flag link:
Amicus’ latest positive update on Pompe drug hints at accelerated approval pitch
Amicus’ latest positive update on Pompe drug hints at accelerated approval pitch
Endpoints
Amicus Therapeutics
Pompe disease
ATB200/AT2221
Flag link:
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Stat
biotech
Axovant Sciences
intepirdine
SAGE Therapeutics
brexanolone
AbbVie
risankizumab
Global Blood Therapeutics
GBT-440
DBV Technologies
Viaskin Peanut
Cytokinetics
Amicus Therapeutics
ATB200
Spark Therapeutics
Bluebird Bio
Revance Therapeutics
RT002
Flag link:
Signaling a major shift at the FDA, regulators put Amicus’ once-spurned drug on fast track
Signaling a major shift at the FDA, regulators put Amicus’ once-spurned drug on fast track
Endpoints
FDA
Amicus Therapeutics
migalastat
Fabry disease
fast track
Flag link:
FDA Reverses Decision, Allowing Amicus To File For Rare Disease Drug
FDA Reverses Decision, Allowing Amicus To File For Rare Disease Drug
Forbes
FDA
Amicus Therapeutics
Rare Diseases
Fabry disease
migalastat
Flag link:
Are These 2 Biotechs Diamonds in the Rough?
Are These 2 Biotechs Diamonds in the Rough?
Motley Fool
biotech
Amicus Therapeutics
Adamas Pharmaceuticals
ADS-5102
Galafold
Flag link:
Biotechs Breaking Out On Drug Development News
Biotechs Breaking Out On Drug Development News
Forbes
Bluebird Bio
Esperion Therapeutics
Amicus Therapeutics
Kite Pharma
Flag link:
Four biotech stocks surging on optimism about drug trials, product launches
Four biotech stocks surging on optimism about drug trials, product launches
Marketwatch
clinical trials
Bluebird Bio
Amicus Therapeutics
Kite Pharma
NeuroDerm
Flag link:
4 Biopharma Stocks Moving the Market on Wednesday
4 Biopharma Stocks Moving the Market on Wednesday
Yahoo/24-7 Wall St
Skyline Medical
Dynavax Technologies
Amicus Therapeutics
Pacira
Flag link:
These Small Biotechs Are Poised to Go Higher
These Small Biotechs Are Poised to Go Higher
Investopedia
biotech
Blood Therapeutics
Versartis
Amicus Therapeutics
Flag link:
Key FDA Decision And Trial Dates In February
Key FDA Decision And Trial Dates In February
Seeking Alpha
FDA
Amgen
Valeant Pharmaceuticals
Amphastar
Egalet
Lexicon Pharmaceuticals
Amicus Therapeutics
Axovant
Flag link:
FDA Requests Additional Data on Amicus’ Fabry Disease Treatment
FDA Requests Additional Data on Amicus’ Fabry Disease Treatment
Yahoo/24-7 Wall St
Fabry disease
FDA
Amicus Therapeutics
Flag link:
5 Small-Cap Biotechs With Big Potential
5 Small-Cap Biotechs With Big Potential
TheStreet.com
biotech
Portola Pharmaceuticals
Progenics
Redhill Biopharma
Dynavax
Amicus Therapeutics
Flag link:
Amicus' Fabry disease drug gets European Commission approval
Amicus' Fabry disease drug gets European Commission approval
Yahoo/Reuters
Amicus Therapeutics
Fabry's disease
Europe
migalastat
Flag link:
Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters
Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters
TheStreet.com
Amicus Therapeutics
FDA
Flag link:
Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline
Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline
TheStreet.com
Amicus Therapeutics
Scioderm
M&A
Flag link:

Pages